指南与共识药疹与重症皮肤不良反应

EGFR抑制剂相关痤疮样皮疹管理:欧美首个德尔菲共识

Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2024-10-26

该立场文件基于欧洲/美国德尔菲共识流程,由欧洲皮肤病与性病学学会癌症患者皮肤病学工作组主导,邀请32名专家对84条关于EGFR抑制剂相关痤疮样皮疹诊治的陈述进行两轮匿名投票。75条(89.3%)达成强共识,6条达成中度共识,3条未达成共识。关键推荐包括低剂量异维A酸用于难治性II/III级皮疹、维持期使用局部吡美莫司等保类固醇药物、以及多西环素100或200 mg/日用于预防。

要点

  • 难治性II/III级EGFRi相关痤疮样皮疹可考虑低剂量异维A酸。
  • 维持期推荐局部保类固醇药物如吡美莫司。
  • 多西环素100或200 mg/日可用于预防,不推荐局部抗生素。

核心结论

  • 该共识为EGFR抑制剂相关痤疮样皮疹的管理提供了统一国际指导,尤其关注放疗科医生、全科医生、皮肤科医生和肿瘤科医生常忽视的要点。

研究设计与样本

  • 由欧洲皮肤病与性病学学会癌症患者皮肤病学工作组五名成员主导制定问卷,发送给欧洲、加拿大、阿根廷、美国和亚洲的32名支持性肿瘤皮肤病学专家。
  • 问卷共84条陈述,涉及EGFRi相关痤疮样皮疹的诊断和治疗,专家采用匿名5点Likert量表回答。
  • 第一轮共识定义为≥75%同意或强烈同意(阳性共识)或不同意或强烈不同意(阴性共识);未达强共识的陈述根据反馈修订后进行第二轮调查。

主要发现

  • 75/84条(89.3%)陈述达成强共识,6/84条达成中度共识,3/84条未达成共识。
  • 未达成共识的3条主要与缺乏稳健数据有关。

关键数值与推荐

  • 难治性II/III级痤疮样皮疹可考虑低剂量异维A酸。
  • 维持期可使用局部保类固醇药物如局部吡美莫司。
  • 多西环素100或200 mg/日可用于预防性治疗。
  • 专家不推荐局部抗生素用于预防或治疗。

临床怎么用

  • 皮肤科医生可参考该共识管理EGFRi相关痤疮样皮疹,包括难治性皮疹的低剂量异维A酸使用、维持期局部吡美莫司以及多西环素预防。
  • 应避免局部抗生素用于预防或治疗EGFRi相关痤疮样皮疹。

局限性

  • 3/84条陈述未达成共识,主要因缺乏稳健数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists. OBJECTIVE: To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus. METHODS: The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi-induced acneiform rash. Experts responded to an anonymous 5-point Likert scale survey. The coordinators collected the first-round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second-round survey. RESULTS: Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low-dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid-sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics. CONCLUSION: This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Apalla Z, Freites-Martinez A, Grafanaki K, et al. Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process. J Eur Acad Dermatol Venereol. 2024. PMID: 39460590. doi:10.1111/jdv.20391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。